Bristol Myers Squibb’s cell therapy gets USFDA nod for relapsed or refractory follicular lymphoma EP News Bureau May 16, 2024 95.7 per cent of patients responded to Breyanzi in the TRANSCEND FL trial
US FDA approves Bristol Myers Squibb’s CAR-T cell therapy Breyanzi for relapsed large B-cell… EP News Bureau Jun 28, 2022 In the pivotal phase-III Transform trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of…
